玻璃体腔注射康柏西普治疗糖尿病黄斑水肿的疗效观察
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Clinical observation of intravitreal injection of Conbercept treating diabetic macularedema
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察玻璃体腔注射康柏西普治疗糖尿病黄斑水肿(diabetic macular edema,DME)的有效性及安全性。

    方法:前瞻性研究。选取2015-12/2016-12在深圳市人民医院眼科就诊,经荧光素眼底血管造影(fluorescein fundus angiography,FFA)及光学相干断层扫描(optical coherence tomography,OCT)检查确诊的DME患者20例20眼纳入本研究。采用糖尿病视网膜病变早期治疗研究视力表(ETDRS)检查最佳矫正视力(best corrected visual acuity,BCVA),OCT检查测量黄斑中心厚度(central macular thickness,CMT)。所有患眼玻璃体腔注射10mg/mL康柏西普0.05mL(含康柏西普0.5mg),每1mo注射1次,连续3次为核心治疗,之后根据病情需要决定是否重复治疗。每1mo随访1次,平均随访时间8.55±1.96mo。对比分析治疗前后患眼BCVA、CMT及黄斑水肿渗漏的变化,同时观察随访期间眼部与全身不良反应的发生情况。

    结果:治疗前,患眼平均BCVA为43.35±17.45个字母,平均CMT为576.30±167.92μm。患眼平均注射次数3.20±0.52次。治疗后1、3、6mo及末次随访时,患眼平均BCVA均较治疗前分别提高11.2±5.9、13.8±7.9、15.7±6.8、14.7±8.6个字母,差异均有显著统计学意义(均P<0.01)。治疗后1mo平均BCVA提高的字母数与术后6mo及末次随访相比,差异均有显著统计学意义(P<0.01); 末次随访时,视力显著提高者10眼(50%); 提高者7眼(35%); 稳定者3眼(15%)。治疗后1、3、6mo及末次随访时,患眼平均CMT较治疗前分别降低了183.8±159.5、292.9±169.0、271.4±167.2、286.4±166.9μm,差异均有显著统计学意义(P<0.01),治疗后1mo平均CMT与术后3、6mo及末次随访相比,差异均有显著统计学意义(P<0.01)。末次随访时FFA检查发现,黄斑水肿消失者6眼(30%); 水肿减轻者12眼(60%); 水肿范围扩大者2眼(10%)。随访期间均未见视网膜脱离、眼压持续升高、眼内炎等与治疗相关的严重眼部及全身并发症。

    结论:玻璃体腔注射康柏西普治疗DME可提高患眼视力,降低患眼CMT,安全性好。

    Abstract:

    AIM: To observe the clinical efficiency of intravitreal conbercept on diabetic macular edema(DME).

    METHODS: This was a single arm, open-babel prospective study. Twenty eyes from 20 patients(12 males and 8 females)with DME diagnosed by fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were enrolled. Before the injection, best-corrected visual acuity(BCVA)of early treatment of diabetic retinopathy study(ETDRS), non-contact tonometer, ophthalmoscope, fundus photography, fundus fluoresein angiograph(FFA), and OCT were examined. All affected eyes were treated with intravitreal conbercept 0.05mL(10mg/mL). Patients were followed up for 6 to 11mo, with a mean duration of 8.55±1.96mo. Post-treatment BCVA, CMT, leakage of macular edema and complications were compared with baseline using repeat analysis.

    RESULTS: The initial average visual acuity(ETDRS letters)were 43.35±17.45, range from 9 to 70. The initial average central macular thickness(CMT)was 576.30±167.92μm, range from 337 to 987μm. The mean BCVA showed significant improvement during 1, 3, 6mo post-treatment and the latest follow up, with a mean increase of 11.2±5.9, 13.8±7.9, 15.7±6.8 and 14.7±8.6, respectively(P<0.01). The changes of BCVA between before and at 1mo after treatment were different compared with the changes between before and at 6mo(P<0.01). During the latest follow up, the mean BCVA was obviously improved in 10 eyes(50%), improved in 7 eyes(35%), stable in 3 eyes(15%). Likewise, the mean CMT significantly decreased during the follow-up period with a mean CMT reduction of 183.8±159.5, 292.9±169.0, 271.4±167.2 and 286.4±166.9μm respectively(P<0.001). The CMT at 1mo were different with that 3, 6mo and final follow-up(P<0.01). During the latest follow up, macula lutea leakage disappeared in 6 eyes(30%), decreased in 12 eyes(60%)and increased in 2 eyes(10%). No adverse events such as secondary retinal detachment or endophthalmitis were found during the follow-up.

    CONCLUSION: Intravitreal conbercept significantly improve visual acuity and macular edema exudation.

    参考文献
    相似文献
    引证文献
引用本文

蒋莉,李劲,聂爱芹.玻璃体腔注射康柏西普治疗糖尿病黄斑水肿的疗效观察.国际眼科杂志, 2017,17(6):1105-1107.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2017-02-17
  • 最后修改日期:2017-05-05
  • 录用日期:
  • 在线发布日期: 2017-05-24
  • 出版日期:
文章二维码